Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Eli Lilly -- Ignore unavailable to you. Want to Upgrade?

To: Jack Stirling who wrote (235)	5/28/1998 10:42:00 PM
From: James Baker	Read Replies (1) \| Respond to of 642

Jack I have no idea why you thought that - wish it were true. Sad truth for us LLY owners is that Evista is approved for osteoporosis prevention only at this time. Studies to fully prove the breast cancer prevention and heart disease prevention benefits of E are probably years away. Now that said the drug is approved and on the market and some patients and docs may decide to run with the info as presented at the oncology meeting s that E prevents 60-70% of breast cancers in the general population of post-menapausal women. that makes it a very attractive choice for osteop. prevention indeed. Jim

To: Jack Stirling who wrote (235)	5/28/1998 11:21:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 642

Jack, I've stopped trying to make sense of the market in valuing individual stocks. Now it seems that even momentum players have jumped into pharmaceuticals, and LLY is perceived, rightly or wrongly, to have less momentum than some other pharmas, such as WLA and PFE. At this price, don't you feel that it has less downside than a lot of other stocks? Don't believe LLY would go much lower than $61/$62; it'll be in a trading range between the low 60's and high 60's for a while.